The debate over the proposed merger of Union Hospital and Terre Haute Regional Hospital under Indiana’s Certificate of Public Advantage (COPA) law has drawn significant attention. The Federal Trade Commission (FTC) has pointed out several issues with the merger, critiquing potential increases in
The opioid crisis has left an indelible mark on American society, thrusting numerous stakeholders, particularly drug distributors, into the spotlight. The recent $300 million settlement by McKesson, Cardinal, and Cencora represents one of the latest significant efforts to address the multifaceted
The recent decision by the U.S. Department of Health and Human Services (HHS) to appeal a district court ruling on the use of online tracking technologies in healthcare has sent ripples through the industry. This legal battle pits concerns about patient data privacy against the operational needs of
Medicare, the federal health insurance program designed to serve individuals aged 65 and older, faces substantial financial challenges that are growing increasingly severe. Recently, a spotlight has been placed on the potential repercussions of including semaglutide, a high-cost medication
Johnson & Johnson (J&J), one of the leading pharmaceutical companies globally, has announced significant changes to its participation in the 340B drug discount program. Effective October 15, the company will cease providing upfront discounts on two key drugs and move to a rebate system instead,
As the end of 2024 approaches, the 118th Congress and various executive agencies in the United States are in a heated race to finalize significant health technology policies. This effort spans telehealth policies, health data privacy, cybersecurity, healthcare Artificial Intelligence (AI), and
